View More Recent Stories
-
Unicycive Therapeutics (UNCY) Announces Submission of NDA to U.S. FDA for Oxylanthanum Carbonate for Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
-
Unicycive Therapeutics (UNCY) PT Lowered to $2.50 at H.C. Wainwright
-
Unicycive Therapeutics, Inc. (UNCY) Misses Q2 EPS by 9c
-
Unicycive Therapeutics, Inc (UNCY) Receives US Patent for UNI-494 to Treat Acute Kidney Injury
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
Unicycive Therapeutics (UNCY) Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate
-
Unicycive Therapeutics (UNCY) Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
